Influence of Levocarnitin Treatment during a Stable Ischemic Heart Disease in Patients with Non-Alcoholic Fatty Liver Disease and Obesity
Journal Title: Український журнал медицини, біології та спорту - Year 2017, Vol 6, Issue 4
Abstract
Metabolic syndrome which is accompanied by excess body weight is a predictor of ischemic myocardial defeat in ischemic heart disease (IHD) and non-alcoholic fatty liver disease (NAFLD). Among the medicines that provide the normalization of metabolic status, correcting dyslipidemia, we would like to emphasize levocarnitine, which has anabolic effect, reduces the main metabolism, and has antihypoxic, lipid metabolism stimulating pharmacological effect. The purpose of the study is to determine the effect of levocarnitine on the progression of IHD in combination with NAFLD and obesity. Materials and methods. The surveyed patients (68 patients with an average age of 70.32 ± 6.71 years, 0.90 (M ± SEM; SD)) were divided into two groups: the main group and the comparison group. The main group consisted of 35 patients who received levocarnitine at a dose of 20 mg/kg/day intravenously for 10 days during the period of stay in the hospital, and subsequently on the stage of outpatient treatment continued the therapy per os – 1g 2 twice a day at the background of the standard IHD pharmacotherapy for another 21 days. The control group consisted of 33 patients who received exclusively standard IHD therapy. In both groups, in addition to the general clinical trial, daily monitoring of the ECG was performed (before and after 1 month of treatment) using the Holter system "LABTECH Ltd", software version V4.04.RC14), determination of lipidogram indicators (total chol esterol level (TCL), Triglycerides (TG), low-density lipoprotein (LDL-C) and high density (HDL-C), an atherogenicity index (AI)). The presence of NAFLD (fatty liver infiltration) was diagnosed with ultrasound examination of the abdominal organs on the Logiq F8 («General Electric») apparatus. Results and discussions. As a result of the study, significant decrease in the number of episodes and duration of ischemia periods per day in all patients and a tendency to decrease of cardiac rhythm disturbance in the background of treatment with a significant advantage in the group receiving additionally levocarnitine was noticed.
Authors and Affiliations
T. Shevchenko, S. Sorokina, I. Kudrya, O. Shaposhnyk
Keywords
Related Articles
- EP ID EP273387
- DOI -
- Views 103
- Downloads 0
Physical Rehabilitation of Psychonevrological Assylum Elderly Patients with Femoral Neck Fracture without Complications
Problems of curing various types of injuries are quite widely covered in the Ukrainian and foreign literature but quite insufficiently. The organization of trauma and orthopedic care and the prevention of injuries are no...
THE EFFECT OF VANADIUM CITRATE ON THE METABOLISM OF PROTEINS IN RATS’ BLOOD WITH ALLOXAN-INDUCED DIABETES MELLITUS
The effect of vanadium citrate on the content of total protein and its fractions, urea and creatinine, as well as the activity of ASAT, ALAT and alkaline phosphatase in the blood plasma of experimentally diabetic rats wa...
The Principle of Maximum Life Length Calculation
According to Bertrand Russell, reasonable arguments in science without using mathematical formulas (mathematical models) sometimes lead to false conclusions. Therefore, there is a justified desire to seek an explanation...
SOME PECULIARITIES OF LATE REPRODUCTIVE AGE WOMEN WITH DIABETES BEFORE HYSTERECTOMY
Hysterectomy is the most common gynecological surgery in most countries which is performed for women in perimenopause. Post ovariectomy syndrome is characterized for women with this problem, which is manifested as vegeta...
ВЛИЯНИЕ ТЕРАПИИ НА УРОВНИ БИОМАРКЕРОВ ВОСПАЛЕНИЯ Р-СЕЛЕКТИНА И ГАЛЕКТИНА-3 У БОЛЬНЫХ СТАБИЛЬНОЙ СТЕНОКАРДИЕЙ В СОЧЕТАНИИ С САХАРНЫМ ДИАБЕТОМ 2 ТИПА
Изучение влияния стандартной и специфической терапии у больных со стенокардией и сахарным диабетом 2 типа может дать обоснование индивидуализиции терапии, направленной на снижение «остаточного» сердечно-сосудистого риска...